Skip to content

Study · Non-randomized trial · 2024

6 results

Effect analysis of entecavir on serum hyaluronic acid, laminin and IV collagen in the treatment of hepatitis B E-antigen-positive chronic hepatitis B.

Qian J, Sun X, Cheng Y

African health sciences1 Dec 2024

PMID40190501 (opens in a new tab)PMCIDPMC11970162 (opens in a new tab)DOI10.4314/ahs.v24i4.6 (opens in a new tab)PepBankPUB-40190501
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

BackgroundTo observe and analyse the clinical effects of entecavir on serum hyaluronic acid (HA), laminin (LN), and type IV collagen (IVC) in patients with hepatitis B e-antigen (HBeAG)-positive chronic hepatitis B during clinical treatment.MethodologyThe patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy. The clinical curative effects of immune checkpoint inhibitors at different concentrations on diseases were compared from all aspects.ResultsThere were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P<0.05). The levels of liver function indicators, immune function-related indicators (CD3+, CD4+, CD8+, CD4+/CD8+, CD4+/CD8+), and HA, LN and IVC were not statistically different between the two groups before treatment.ConclusionEntecavir is highly effective in the clinical treatment of HBeAG-positive chronic hepatitis B. However, entecavir + thymalfasin combination therapy can alleviate the clinical symptoms. In this way, liver fibrosis can be prevented in patients with HBeAG-positive chronic hepatitis B, and the clinical curative effect can be enhanced.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In HBeAg-positive chronic hepatitis B, thymalfasin plus entecavir gave lower total bilirubin than entecavir alone.

    In plain wordsIn people with chronic hepatitis B, adding thymalfasin to entecavir gave lower bilirubin than entecavir alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseTotal bilirubin (TBIL)
    Study

    n: not reported in source

    Comparator
    Entecavir monotherapy
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P<0.05).
    1 context sentence
    Summary · context
    The patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy.
  2. 02HumanNon-randomized trialEfficacy outcome

    In HBeAg-positive chronic hepatitis B, thymalfasin plus entecavir gave lower ALT than entecavir alone.

    In plain wordsIn people with chronic hepatitis B, adding thymalfasin to entecavir gave lower ALT than entecavir alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseAlanine transaminase (ALT)
    Study

    n: not reported in source

    Comparator
    Entecavir monotherapy
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P<0.05).
    1 context sentence
    Summary · context
    The patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy.
  3. 03HumanNon-randomized trialEfficacy outcome

    In HBeAg-positive chronic hepatitis B, thymalfasin plus entecavir gave a more satisfactory improvement in immune function-related indicators than entecavir alone.

    In plain wordsIn people with chronic hepatitis B, adding thymalfasin to entecavir improved immune function measures more than entecavir alone.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedImmune function-related indicators
    Study

    n: not reported in source

    Comparator
    Entecavir monotherapy
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P<0.05).
    1 context sentence
    Summary · context
    The patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy.
  4. 04HumanNon-randomized trialEfficacy outcome

    In HBeAg-positive chronic hepatitis B, thymalfasin plus entecavir gave lower serum hyaluronic acid than entecavir alone.

    In plain wordsIn people with chronic hepatitis B, adding thymalfasin to entecavir gave lower hyaluronic acid, a liver scarring marker, than entecavir alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum hyaluronic acid (HA)
    Study

    n: not reported in source

    Comparator
    Entecavir monotherapy
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P<0.05).
    1 context sentence
    Summary · context
    The patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy.
  5. 05HumanNon-randomized trialEfficacy outcome

    In HBeAg-positive chronic hepatitis B, thymalfasin plus entecavir gave lower serum laminin than entecavir alone.

    In plain wordsIn people with chronic hepatitis B, adding thymalfasin to entecavir gave lower laminin, a liver scarring marker, than entecavir alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum laminin (LN)
    Study

    n: not reported in source

    Comparator
    Entecavir monotherapy
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P<0.05).
    1 context sentence
    Summary · context
    The patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy.
  6. 06HumanNon-randomized trialEfficacy outcome

    In HBeAg-positive chronic hepatitis B, thymalfasin plus entecavir gave lower serum type IV collagen than entecavir alone.

    In plain wordsIn people with chronic hepatitis B, adding thymalfasin to entecavir gave lower type IV collagen, a liver scarring marker, than entecavir alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum type IV collagen (IVC)
    Study

    n: not reported in source

    Comparator
    Entecavir monotherapy
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were lower levels of total bilirubin (TBIL) and alanine transaminase (ALT) in the observation group, a more satisfactory improvement in immune function-related indicators, and lower levels of HA, LN, and IVC in the observation group, which were statistically different between the two groups (P<0.05).
    1 context sentence
    Summary · context
    The patients in the control group received clinical treatment with entecavir monotherapy, while those in the observation group underwent thymalfasin + entecavir combination therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.